Anti-ALK/ CD246/ NBLST3 monoclonal antibody
Anti-ALK/ CD246/ NBLST3 antibody for FACS & in-vivo assay
Go to ALK/ALK products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T56418-Ab-1/ GM-Tg-hg-T56418-Ab-2 | Anti-Human ALK monoclonal antibody | Human |
GM-Tg-rg-T56418-Ab-1/ GM-Tg-rg-T56418-Ab-2 | Anti-Rat ALK monoclonal antibody | Rat |
GM-Tg-mg-T56418-Ab-1/ GM-Tg-mg-T56418-Ab-2 | Anti-Mouse ALK monoclonal antibody | Mouse |
GM-Tg-cynog-T56418-Ab-1/ GM-Tg-cynog-T56418-Ab-2 | Anti-Cynomolgus/ Rhesus macaque ALK monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T56418-Ab-1/ GM-Tg-felg-T56418-Ab-2 | Anti-Feline ALK monoclonal antibody | Feline |
GM-Tg-cang-T56418-Ab-1/ GM-Tg-cang-T56418-Ab-2 | Anti-Canine ALK monoclonal antibody | Canine |
GM-Tg-bovg-T56418-Ab-1/ GM-Tg-bovg-T56418-Ab-2 | Anti-Bovine ALK monoclonal antibody | Bovine |
GM-Tg-equg-T56418-Ab-1/ GM-Tg-equg-T56418-Ab-2 | Anti-Equine ALK monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T56418-Ab-1/ GM-Tg-hg-T56418-Ab-2; GM-Tg-rg-T56418-Ab-1/ GM-Tg-rg-T56418-Ab-2; GM-Tg-mg-T56418-Ab-1/ GM-Tg-mg-T56418-Ab-2; GM-Tg-cynog-T56418-Ab-1/ GM-Tg-cynog-T56418-Ab-2; GM-Tg-felg-T56418-Ab-1/ GM-Tg-felg-T56418-Ab-2; GM-Tg-cang-T56418-Ab-1/ GM-Tg-cang-T56418-Ab-2; GM-Tg-bovg-T56418-Ab-1/ GM-Tg-bovg-T56418-Ab-2; GM-Tg-equg-T56418-Ab-1/ GM-Tg-equg-T56418-Ab-2 |
Products Name | Anti-ALK monoclonal antibody |
Format | mab |
Target Name | ALK |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-ALK benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species ALK/ CD246/ NBLST3 VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMAD000452 | house mouse Alk Adenovirus plasmid |
ORF Viral Vector | vGMAD000452 | house mouse Alk Adenovirus particle |
Target information
Target ID | GM-T56418 |
Target Name | ALK |
Gene ID | 238,11682,266802,704823,483021,101091689,536642 |
Gene Symbol and Synonyms | ALK,ALK1,CD246,NBLST3,Tcrz |
Uniprot Accession | Q9UM73,P0DV84 |
Uniprot Entry Name | ALK_HUMAN,- |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, Immuno-oncology Target |
Disease | Non-Small Cell Lung Cancer, Anaplastic large cell carcinoma (ALCL), Anaplastic Large Cell Lymphoma (ALCL) |
Gene Ensembl | ENSG00000171094 |
Target Classification | Checkpoint-Immuno Oncology, Kinase |
The target: ALK, gene name: ALK, also named as CD246, NBLST3. This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, an hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. It plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. This gene has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer. The chromosomal rearrangements are the most common genetic alterations in this gene, which result in creation of multiple fusion genes in tumourigenesis, including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3), ALK/NPM1 (chromosome 5), ALK/SQS™1 (chromosome 5), ALK/KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (chromosome X).[provided by RefSeq, Jan 2011].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.